BC Extra | Jun 14, 2017
Financial News

GenMark raises $75M in upsized follow-on

Molecular diagnostics company GenMark Diagnostics Inc. (NASDAQ:GNMK) raised $75 million through the sale of 6.4 million shares at $11.75 in an upsized follow-on underwritten by JPMorgan, BofA Merrill Lynch, William Blair, Cowen and Raymond James....
BC Week In Review | Jul 22, 2013
Company News

Theradiag sales and marketing update

Theradiag launched two molecular diagnostic assays - the xTAG Gastrointestinal Pathogen Panel (GPP) assay and the xTAG Respiratory Viral Panel (RVP) FAST assay. The xTAG GPP simultaneously detects 11 gastrointestinal pathogens, including bacteria, viruses and parasites,...
BC Week In Review | Sep 24, 2012
Clinical News

ESensor Respiratory Virus Panel regulatory update

GenMark said FDA granted 510(k) clearance for its eSensor Respiratory Virus Panel to detect and differentiate 14 clinically relevant viruses from patients with influenza-like illness. GenMark said the respiratory viral panel test can distinguish rhinovirus...
BioCentury | Jul 23, 2012
Emerging Company Profile

Xagenic: PCR-free diagnosis

PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc. 's chip-based arrays use a non-PCR,...
BC Week In Review | Jan 2, 2012
Clinical News

Respiratory Viral Panel regulatory update

GenMark submitted a 510(k) application to FDA for its Respiratory Viral Panel (RVP) to identify multiple viruses from patients with symptomatic respiratory infection. The test, which runs on GenMark's eSensor XT-8 system, is a qualitative...
BC Week In Review | Sep 7, 2009
Company News

ViraCor-IBT sales and marketing update

ViraCor-IBT Laboratories , Kansas City, Kan.   Business: Diagnostic   ViraCor-IBT launched an influenza and respiratory virus testing service that includes: xTAG Respiratory Viral Panel (RVP) for 12 viral targets, including influenza A and B and...
BC Week In Review | Apr 13, 2009
Clinical News

Influenza detection system: Post-marketing study data

Data from a post-marketing study in 75 clinical specimens showed that CombiMatrix's influenza detection system achieved 95.2% sensitivity and 100% selectivity in detecting influenza A H3N2 and H1N1 subtypes compared with xTAG Respiratory Viral Panel...
BC Week In Review | Oct 13, 2008
Clinical News

xTAG Respiratory Viral Panel regulatory update

Health Canada granted marketing approval for Luminex's xTAG Respiratory Viral Panel (RVP) to detect 18 respiratory viruses, including strains of influenza, respiratory syncytial virus (RSV), metapneumovirus, adenovirus and rhinovirus. Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.)...
BC Week In Review | Mar 10, 2008
Company News

Luminex, Abbott sales and marketing update

Abbott received semi-exclusive rights in the U.S. and exclusive rights elsewhere to distribute Luminex's xTAG Respiratory Viral Panel (RVP). The assay is cleared to detect and identify 12 respiratory viruses in the U.S., including strains...
BC Week In Review | Dec 4, 2006
Clinical News

ID-Tag RVP: Pivotal trial data

In the European arm of an international pivotal trial in more than 1,000 patient specimens, ID-Tag RVP was able to detect the bird flu virus (H5 subtype of influenza A) in all positive clinical samples....
Items per page:
1 - 10 of 12